L
Lineage Cell Therapeutics Inc
TASE:LCTX
Lineage Cell Therapeutics Inc
TASE:LCTX
Price:
598.8
ILS
1.03%
Market Cap:
₪473.5m
Balance Sheet
Balance Sheet Decomposition
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
Balance Sheet Decomposition is not available for
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
Balance Sheet
Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc
Currency: USD
| Dec-2001 | Dec-2002 | Dec-2003 | Dec-2004 | Dec-2005 | Dec-2006 | Dec-2007 | Dec-2008 | Dec-2009 | Dec-2010 | Dec-2011 | Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||
| Cash & Cash Equivalents |
2
|
1
|
1
|
1
|
2
|
1
|
0
|
0
|
12
|
33
|
22
|
4
|
6
|
30
|
42
|
22
|
37
|
24
|
10
|
33
|
56
|
11
|
35
|
46
|
|
| Cash Equivalents |
2
|
1
|
1
|
1
|
2
|
1
|
0
|
0
|
12
|
33
|
22
|
4
|
6
|
30
|
42
|
22
|
37
|
24
|
10
|
33
|
56
|
11
|
35
|
46
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
7
|
21
|
9
|
3
|
47
|
0
|
2
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
2
|
1
|
3
|
4
|
24
|
0
|
51
|
0
|
1
|
1
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
1
|
1
|
1
|
1
|
0
|
1
|
0
|
0
|
51
|
0
|
1
|
1
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
0
|
1
|
0
|
1
|
3
|
3
|
24
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
1
|
1
|
3
|
2
|
1
|
2
|
3
|
2
|
2
|
2
|
2
|
3
|
|
| Total Current Assets |
2
|
1
|
1
|
2
|
2
|
1
|
0
|
0
|
12
|
36
|
25
|
7
|
8
|
32
|
47
|
26
|
43
|
36
|
58
|
44
|
112
|
60
|
38
|
51
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
3
|
8
|
6
|
6
|
6
|
8
|
6
|
5
|
6
|
5
|
4
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
3
|
8
|
6
|
6
|
6
|
8
|
6
|
5
|
6
|
5
|
4
|
|
| Accumulated Depreciation |
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
1
|
2
|
3
|
3
|
3
|
3
|
5
|
4
|
5
|
6
|
7
|
4
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
19
|
21
|
46
|
39
|
34
|
10
|
7
|
3
|
48
|
47
|
47
|
47
|
47
|
47
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
11
|
11
|
11
|
11
|
11
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
22
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
100
|
117
|
34
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
11
|
11
|
11
|
11
|
11
|
11
|
|
| Total Assets |
2
N/A
|
2
-21%
|
1
-27%
|
2
+36%
|
2
+33%
|
1
-65%
|
0
-71%
|
1
+400%
|
13
+1 240%
|
53
+298%
|
46
-14%
|
30
-35%
|
58
+94%
|
75
+30%
|
95
+26%
|
143
+51%
|
173
+21%
|
102
-41%
|
126
+23%
|
108
-14%
|
175
+62%
|
124
-29%
|
101
-18%
|
113
+12%
|
|
| Liabilities | |||||||||||||||||||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
4
|
2
|
3
|
2
|
1
|
2
|
2
|
3
|
4
|
2
|
2
|
1
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
4
|
6
|
5
|
5
|
4
|
4
|
4
|
25
|
7
|
5
|
5
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
3
|
3
|
1
|
3
|
1
|
1
|
0
|
0
|
0
|
19
|
9
|
11
|
7
|
|
| Total Current Liabilities |
0
|
1
|
3
|
1
|
1
|
1
|
2
|
3
|
1
|
3
|
3
|
4
|
7
|
7
|
13
|
9
|
7
|
7
|
7
|
8
|
47
|
19
|
18
|
14
|
|
| Long-Term Debt |
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
5
|
3
|
1
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
8
|
5
|
0
|
0
|
0
|
0
|
3
|
2
|
2
|
2
|
0
|
0
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
11
|
13
|
15
|
28
|
26
|
50
|
13
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
0
|
0
|
1
|
0
|
1
|
1
|
4
|
3
|
34
|
31
|
21
|
22
|
|
| Total Liabilities |
2
N/A
|
3
+35%
|
4
+30%
|
1
-66%
|
2
+83%
|
3
+14%
|
3
+28%
|
5
+69%
|
6
+19%
|
15
+136%
|
17
+14%
|
20
+17%
|
43
+112%
|
38
-10%
|
68
+77%
|
25
-64%
|
11
-57%
|
8
-26%
|
13
+60%
|
12
-6%
|
82
+597%
|
50
-39%
|
38
-25%
|
35
-7%
|
|
| Equity | |||||||||||||||||||||||||
| Common Stock |
31
|
32
|
33
|
39
|
40
|
40
|
41
|
43
|
60
|
101
|
115
|
120
|
204
|
238
|
274
|
318
|
379
|
354
|
387
|
394
|
435
|
440
|
451
|
485
|
|
| Retained Earnings |
31
|
34
|
35
|
39
|
41
|
42
|
44
|
48
|
53
|
64
|
81
|
102
|
146
|
182
|
229
|
196
|
216
|
262
|
273
|
294
|
337
|
363
|
385
|
403
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
8
|
43
|
20
|
18
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
4
|
5
|
4
|
3
|
3
|
|
| Total Equity |
0
N/A
|
1
-1 100%
|
2
-100%
|
0
N/A
|
0
N/A
|
2
-850%
|
3
-58%
|
4
-43%
|
7
N/A
|
38
+446%
|
29
-25%
|
10
-66%
|
15
+54%
|
37
+147%
|
27
-26%
|
118
+338%
|
163
+38%
|
94
-42%
|
113
+20%
|
96
-15%
|
92
-4%
|
73
-20%
|
63
-13%
|
78
+24%
|
|
| Total Liabilities & Equity |
2
N/A
|
2
-21%
|
1
-27%
|
2
+36%
|
2
+33%
|
1
-65%
|
0
-71%
|
1
+400%
|
13
+1 240%
|
53
+298%
|
46
-14%
|
30
-35%
|
58
+94%
|
75
+30%
|
95
+26%
|
143
+51%
|
173
+21%
|
102
-41%
|
126
+23%
|
108
-14%
|
175
+62%
|
124
-29%
|
101
-18%
|
113
+12%
|
|
| Shares Outstanding | |||||||||||||||||||||||||
| Common Shares Outstanding |
12
|
14
|
14
|
18
|
22
|
23
|
23
|
25
|
34
|
48
|
49
|
49
|
57
|
78
|
90
|
103
|
127
|
127
|
150
|
153
|
170
|
170
|
175
|
220
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
